Table of Contents
1. Executive Summary
2. Market Background and Classifications
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2014 to 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Nucleic-Acid Therapeutics Market Trends and Forecast
3.3: Global Nucleic-Acid Therapeutics Market by Technology
3.3.1: Anti-Sense And Anti-Gene
3.3.2: Short Inhibitory Sequences
3.3.3: Gene Transfer Therapy
3.3.4: Nucleoside Analogs
3.3.5: Ribozymes
3.3.6: Aptamers
3.3.7: Others
3.4: Global Nucleic-Acid Therapeutics Market by Application
3.4.1: Monogenetic Disorders
3.4.2: Multi-Genetic Disorders
3.5: Global Nucleic-Acid Therapeutics Market by End User
3.5.1: Hospitals
3.5.2: Academic & Research Institutes
3.5.3: Others
4. Market Trends and Forecast Analysis by Region
4.1: Global Nucleic-Acid Therapeutics Market by Region
4.2: North American Nucleic-Acid Therapeutics Market
4.2.1: Market by Technology: Anti-Sense And Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, and Others
4.2.2: Market by Application: Monogenetic Disorders and Multi-Genetic Disorders
4.2.3: Market by End User: Hospitals, Academic & Research Institutes, and Others
4.2.4: The United States Nucleic-Acid Therapeutics Market
4.2.5: The Canadian Nucleic-Acid Therapeutics Market
4.2.6: The Mexican Nucleic-Acid Therapeutics Market
4.3: European Nucleic-Acid Therapeutics Market
4.3.1: Market by Technology: Anti-Sense And Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, and Others
4.3.2: Market by Application: Monogenetic Disorders and Multi-Genetic Disorders
4.3.3: Market by End User: Hospitals, Academic & Research Institutes, and Others
4.3.4: The Nucleic-Acid Therapeutics Market of United Kingdom
4.3.5: The Spanish Nucleic-Acid Therapeutics Market
4.3.6: The German Nucleic-Acid Therapeutics Market
4.3.7: The French Nucleic-Acid Therapeutics Market
4.4: APAC Nucleic-Acid Therapeutics Market
4.4.1: Market by Technology: Anti-Sense And Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, and Others
4.4.2: Market by Application: Monogenetic Disorders and Multi-Genetic Disorders
4.4.3: Market by End User: Hospitals, Academic & Research Institutes, and Others
4.4.4: The Chinese Nucleic-Acid Therapeutics Market
4.4.5: The Indian Nucleic-Acid Therapeutics Market
4.4.6: The Japanese Nucleic-Acid Therapeutics Market
4.5: ROW Nucleic-Acid Therapeutics Market
4.5.1: Market by Technology: Anti-Sense And Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, and Others
4.5.2: Market by Application: Monogenetic Disorders and Multi-Genetic Disorders
4.5.3: Market by End User: Hospitals, Academic & Research Institutes, and Others
4.5.4: Brazilian Nucleic-Acid Therapeutics Market
5. Competitor Analysis
5.1: Market Share Analysis
5.2: Product Portfolio Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. Cost Structure Analysis
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. Growth Opportunities and Strategic Analysis
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Nucleic-Acid Therapeutics Market by Technology
7.1.2: Growth Opportunities for the Global Nucleic-Acid Therapeutics Market by Application
7.1.3: Growth Opportunities for the Global Nucleic-Acid Therapeutics Market by End User
7.1.4: Growth Opportunities for the Global Nucleic-Acid Therapeutics Market by Region
7.2: Emerging Trends in the Global Nucleic-Acid Therapeutics Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Nucleic-Acid Therapeutics Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Nucleic-Acid Therapeutics Market
7.3.4: Certification and Licensing
8. Company Profiles of Leading Players
8.1: Wave Life Sciences Ltd.
8.2: Copernicus Therapeutics Inc.
8.3: Imugene
8.4: Caperna
8.5: Phylogica
8.6: Protagonist Therapeutics
8.7: Benitec Biopharma
8.8: EGEN (Expression Genetics)
8.9: Benitec Biopharma
8.10: BioMedica (Oxford BioMedica)